Inspira Technologies’ INSPIRA ART100 Achieves First Successful Patient Treatment

Inspira Technologies Oxy BHN ( (IINN) ) has shared an announcement.

On April 7, 2025, Inspira Technologies announced the successful first clinical use of its FDA-cleared INSPIRA ART100 system at Westchester Medical Center in New York. The system provided comprehensive heart and lung support during a critical life-support procedure, marking a significant milestone for the company. This achievement is expected to pave the way for broader adoption of the technology in leading hospitals, facilitated by their U.S. distributor, Glo-Med Networks Inc.

Spark’s Take on IINN Stock

According to Spark, TipRanks’ AI Analyst, IINN is a Underperform.

Inspira Technologies Oxy BHN is currently facing significant financial and operational challenges. The lack of revenue generation and continued losses are major concerns. Technical analysis reflects a bearish outlook with downward momentum and weak price trends. The valuation does not provide enough incentive for investment given the underlying risks.

To see Spark’s full report on IINN stock, click here.

More about Inspira Technologies Oxy BHN

Inspira Technologies Oxy B.H.N. Ltd. is a company pioneering in innovative life-support and diagnostic technologies, focusing on respiratory support and diagnostics. Their flagship product, the INSPIRA ART500 system, aims to revolutionize critical care by allowing patients to remain awake during treatment while stabilizing oxygen levels without mechanical ventilation. The company also develops the HYLA blood sensor technology for continuous, real-time blood monitoring.

YTD Price Performance: -43.81%

Average Trading Volume: 1,216,639

Technical Sentiment Signal: Strong Buy

Current Market Cap: $15.12M

For a thorough assessment of IINN stock, go to TipRanks’ Stock Analysis page.